Engineered immune cells take aim at childhood brain cancers

This early-phase study tests whether a new type of immunotherapy, called B7-H3 CAR T cells, can be safely given directly into the brain or spinal fluid of children and young adults with aggressive brain tumors like DIPG, DMG, or other recurrent central nervous system cancers. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack tumor cells. The goal is to see if this approach is safe and feasible, and to gather early information on how the cells spread and work in the body.